Perimeter Solutions (PRM) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
17 Apr, 2026Executive summary
The annual meeting will be held virtually on May 28, 2026, with voting rights for shareholders of record as of April 7, 2026.
2025 financial highlights include a 16% increase in net sales to $652.9M, an 18% rise in Adjusted EBITDA to $331.7M, and a net loss of $206.4M.
Major investments in 2025 included $26.5M in capital expenditures, $82M in M&A, and $40.4M in share repurchases.
The company renewed key contracts, expanded internationally, and completed strategic acquisitions, including Medical Manufacturing Technologies, LLC.
Voting matters and shareholder proposals
Shareholders will vote on electing eight directors, approving executive compensation (Say on Pay), and ratifying KPMG LLP as auditor for 2026.
The board recommends voting FOR all director nominees and FOR both the Say on Pay and auditor ratification proposals.
Voting is available by mail, phone, or internet, and shareholders can revoke proxies or vote during the meeting.
Board of directors and corporate governance
The board will consist of eight directors post-meeting, with seven non-employee and five independent members.
Board committees (Audit, Compensation, Nominating & Governance, Executive) are composed entirely of independent directors.
The CEO and Co-Chairmen roles are separated to enhance oversight and objectivity.
Annual board and committee evaluations are conducted, and directors are subject to share retention guidelines.
Latest events from Perimeter Solutions
- Q2 2026 net sales up 31%, adjusted EBITDA up 16%, with Monaco acquisition set to drive growth.PRM
Q2 2026 - Q1 2026 net sales up 74% and adjusted EBITDA up 128%, driven by acquisitions and contracts.PRM
Q1 2026 - Director elections, executive pay, and auditor ratification are up for shareholder vote.PRM
Proxy filing - 2025 revenue up 16%, Specialty Products surged, MMT acquired, leverage and net loss increased.PRM
Q4 2025 - $685M acquisition targets recurring revenue growth and market expansion in medical device manufacturing.PRM
M&A Announcement - Q2 2024 sales up 67%, Adjusted EBITDA up 209%, but net income down 58% on higher advisory fees.PRM
Q2 2024 - Q3 2024 sales and EBITDA more than doubled, but non-recurring charges led to a net loss.PRM
Q3 2024 - Market leadership, value-driven growth, and high barriers fuel sustained financial outperformance.PRM
UBS Global Materials Conference - Adjusted EBITDA up 190% to $280M in 2024, driven by Fire Safety and strategic investments.PRM
Q4 2024